TY - JOUR
T1 - Prognostic analysis and a new risk model for Hodgkin lymphoma in Japan
AU - Itoh, Kuniaki
AU - Kinoshita, Tomohiro
AU - Watanabe, Takashi
AU - Yoshimura, Kenichi
AU - Okamoto, Rumiko
AU - Chou, Takaaki
AU - Ogura, Michinori
AU - Hirano, Masami
AU - Asaoku, Hideki
AU - Kurosawa, Mitsutoshi
AU - Maeda, Yoshiharu
AU - Omachi, Ken
AU - Moriuchi, Yukiyoshi
AU - Kasai, Masaharu
AU - Ohnishi, Kazunori
AU - Takayama, Nobuyuki
AU - Morishima, Yasuo
AU - Tobinai, Kensei
AU - Kaba, Harumi
AU - Yamamoto, Seiichiro
AU - Fukuda, Haruhiko
AU - Kikuchi, Masahiro
AU - Yoshino, Tadashi
AU - Matsuno, Yoshihiro
AU - Hotta, Tomomitsu
AU - Shimoyama, Masanori
PY - 2010/4
Y1 - 2010/4
N2 - The Japan Clinical Oncology Group conducted two multicenter phase II trials in 200 patients with advanced Hodgkin lymphoma (HL) in the 1990s. Among 181 patients whose histopathological specimens were available and reviewed by 6 hematopathologists, 167 (92.3%) were diagnosed with HL. Five-year overall survival (OS) among these 167 patients was 88.3%, including 89.2% among nodular sclerosis and 82.2% among mixed cellularity cases. International prognostic score was not closely associated with OS. Seven unfavorable prognostic factors for OS on univariate analysis were male, B symptoms, clinical stage of III or IV, elevated serum LDH, elevated alkaline phosphatase, elevated β2-microglobulin, and pathological subtype (mixed cellularity and lymphocyte depletion). On multivariate analysis, male [HR 3.30 (95% CI 1.15-9.52, p = 0.027)] and elevated serum LDH [HR 2.41 (95% CI 1.07-5.43, p = 0.034)] were independent factors for OS. Based on these prognostic factors, the 5-year OS was 95.7% in the low-risk group (no adverse factor), 87.9% in the intermediate-risk group (1 adverse factor) and 73.3% in the high-risk group (2 adverse factors). This simple prognostic model for HL warrants further validation studies.
AB - The Japan Clinical Oncology Group conducted two multicenter phase II trials in 200 patients with advanced Hodgkin lymphoma (HL) in the 1990s. Among 181 patients whose histopathological specimens were available and reviewed by 6 hematopathologists, 167 (92.3%) were diagnosed with HL. Five-year overall survival (OS) among these 167 patients was 88.3%, including 89.2% among nodular sclerosis and 82.2% among mixed cellularity cases. International prognostic score was not closely associated with OS. Seven unfavorable prognostic factors for OS on univariate analysis were male, B symptoms, clinical stage of III or IV, elevated serum LDH, elevated alkaline phosphatase, elevated β2-microglobulin, and pathological subtype (mixed cellularity and lymphocyte depletion). On multivariate analysis, male [HR 3.30 (95% CI 1.15-9.52, p = 0.027)] and elevated serum LDH [HR 2.41 (95% CI 1.07-5.43, p = 0.034)] were independent factors for OS. Based on these prognostic factors, the 5-year OS was 95.7% in the low-risk group (no adverse factor), 87.9% in the intermediate-risk group (1 adverse factor) and 73.3% in the high-risk group (2 adverse factors). This simple prognostic model for HL warrants further validation studies.
KW - International prognostic score
KW - LDH
KW - Male gender
KW - Multicenter phase II trial
KW - Overall survival
KW - Prognostic factor
UR - http://www.scopus.com/inward/record.url?scp=77950916831&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77950916831&partnerID=8YFLogxK
U2 - 10.1007/s12185-010-0533-9
DO - 10.1007/s12185-010-0533-9
M3 - Article
C2 - 20198461
AN - SCOPUS:77950916831
VL - 91
SP - 446
EP - 455
JO - International Journal of Hematology
JF - International Journal of Hematology
SN - 0925-5710
IS - 3
ER -